<DOC>
	<DOC>NCT01020136</DOC>
	<brief_summary>The purpose is to show that 5 mg Form IV tablet of AG-013736 produces similar drug concentrations in plasma compared to 5 mg Form XLI tablet of AG-013736 after oral dosing under fed conditions.</brief_summary>
	<brief_title>A Bioequivalence Study Of AG-013736 Tablets Under Fed Conditions In Healthy Volunteers</brief_title>
	<detailed_description>To establish bioequivalence between Form IV and Form XLI of AG-013736 tablets</detailed_description>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Healthy male and/or female subjects between the ages of 21 and 47 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12lead electrocardiogram (ECG) and clinical laboratory tests) Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs) An informed consent document signed and dated by the subject or a legally acceptable representative Evidence of significant disease of the blood, kidney, endocrine system, lungs, gastrointestinal, heart, liver, psychiatric, neurologic, or allergic (including drug allergies, but excluding season allergies) Use of tobacco or nicotine containing products (or a positive urine cotinine test). Pregnant or nursing females and females of childbearing potential including those with tubal ligation</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>47 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Bioequivalence Pharmacokinetics</keyword>
</DOC>